Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LAURION Intercepts of 37.70 g/t Gold over 0.50 m, 6.60 g/t Gold over 1.00 m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bausch Lomb Ord Shs T.BLCO

Alternate Symbol(s):  BLCO

Healthcare Medical Devices
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative... see more

Recent & Breaking News (TSX:BLCO)

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Business Wire March 27, 2024

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

Business Wire February 28, 2024

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

GlobeNewswire February 21, 2024

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Business Wire February 21, 2024

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21

Business Wire February 5, 2024

Bausch + Lomb Receives FDA Approval for TENEO(TM) Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Business Wire January 8, 2024

Bausch + Lomb to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2024

Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Business Wire November 15, 2023

Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance

Business Wire November 1, 2023

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meeting

Business Wire October 26, 2023

Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1

Business Wire October 16, 2023

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Business Wire October 4, 2023

Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)

Accesswire September 29, 2023

Bausch + Lomb Completes Acquisition of XIIDRA®

Business Wire September 29, 2023

Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS(TM) in the United States

Business Wire September 26, 2023

Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners

Business Wire September 20, 2023

Bausch + Lomb Announces Pricing of Senior Secured Notes Offering

Business Wire September 14, 2023

Bausch + Lomb Launches MIEBO(TM) (Perfluorohexyloctane Ophthalmic Solution) in the United States

Business Wire September 12, 2023

Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)

Accesswire September 11, 2023

Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

Business Wire September 11, 2023